JAKARTA (THE JAKARTA POST / ASIA NEWS NETWORK) – Indonesian scientists will begin phase III clinical trials of a potential Covid-19 vaccine developed by Chinese biopharmaceutical company Sinovac Biotech on Tuesday, August 11 at six different locations in the provincial capital. from West Java to Bandung. Professor Kusnandi Rusmil from the Faculty of Medicine, University of Padjajaran (Unpad) who is also the head of the clinical trial research team said human trials will begin on August 11, although the number of volunteers registered on Thursday is still half of the target. The target is around 1,600 person, but so far is only about 800 volunteers that have registered. The testing team is looking for a total of 1,620 volunteers, he said, and volunteer registration will be open until August 31. The six locations chosen for the trial were the Unpad Education Hospital, one Unpad campus and four Puskesmas in Bandung, namely Sukapakir, Garuda, Ciumbuleuit and Dago. The trial is expected to end in six months at the earliest.
Vaccine Will Be Tested Into Two Groups
Professor Kusnandi said that half of the 1,620 volunteers will receive a potential vaccine, while the other half will receive a placebo. The test subjects will be randomly divided into two groups. After the first injection, said Prof. Kusnandi, the volunteers will be observed for 30 to 40 minutes to see if there is a reaction to the vaccine. After that we wait for 14 days and then they will receive the second injection. After that we will monitor their health condition for six months. The results will be compared between 2 groups of volunteers based on their immunogenicity and their health.
Chairman and CEO of pharmaceutical BUMN Bio Farma, Honesti Basyir, said that the company is currently conducting a vaccine stability test in its laboratory. “It takes three to four weeks,” said Honesti, adding that the genome of the virus in Indonesia is 99.99% similar to China. He said Bio Farma will increase its production capacity and is ready to produce 250 million doses of Sinovac vaccine per year by December. The company also plans to invest a loan of at least 1.3 trillion rupees ($ 122 million) in infrastructure development and human resources in its research and production units, he said. added. Penny Kusumastuti Lukito, Head of the Food and Drug Supervisory Agency (BPOM), said that his party has collaborated with a clinical trial research team to confirm this phase trial. III can be done in a safe and ethically appropriate manner.